Top Ten most popular articles on Pharmafile.com this week
October is almost over and Halloween is just around the corner, and it’s time for another run-down of the stories that chalked up the most views online this week.
News of Pfizer’s moves to potentially sell its consumer health division have abounded over th epast weeks, and now it looks to be moving into serious talks with interested parties. Celgene is left reeling after abandoning its $710 million inflammatory disease treatment, while Roche is revealed as the greatest pharma spender worldwide in a new report, alongside AstraZeneca who emerged as the top R&D spender overall in the UK.
But the most popular story with our readers this week was the impactful announcement by MSD that it intends to cut away 1,800 staff from its US workforce.
Check out the week’s ten most popular articles on Pharmafile.com now!
Pfizer is planning to launch an auction process to secure its sale and the $15 billion-plus it is looking for for the unit, it has emerged.
Are our pharmacovigilance measures as effective as we think? And why is it important to answer that question, especially now? Matt Fellows investigates the projects underway to ensure we’re headed in the right direction.
Celgene took a gamble when it spent $710 million up-front on an inflammatory disorder treatment, but it now looks likely to have been an expensive failure after Phase 3 results failed to impress.
A new report published by STOP AIDS and Global Justice Now takes aim at three pharmaceutical companies who have taken on treatments developed with public money before then charging fees that now cost the NHS in excess of $1 billion per year.
Sanofi has launched a patent infringement lawsuit against Mylan over its disposable insulin glargine pre-filled pen Lantus as well as vial-drug diabetes products.
New findings of a report by PwC have revealed the biggest spenders in R&D worldwide as global spending hits $700 billion, with Roche coming out on top within the pharmaceutical industry with a total expenditure of $11.4 billion in 2017, a 14% increase on the previous year which brought in a huge 21.9% of its total income.
A study found that Type 3c diabetes was actually more prevalent in the cross-section of the population than the much more commonly known Type 1, and was often misdiagnosed.
AbbVie already know well what it’s like to have a lead candidate in the psoriasis field, after having Humira sat at the top of the heap for years. It may be getting excited again about the potential of its new treatment, risankizumab, to perform strongly in the area after it met all of its primary and secondary endpoints.
GSK’s Strimvelis, its gene therapy treatment for adenosine deaminase deficiency or ‘bubble boy’ syndrome, has been given a positive recommendation by NICE despite the extremely high cost associated with it.
MSD has revealed its intention to cut 1,800 sales positions from its workforce in the US. In their place, the company will add 960 positions with the formation of a new chronic care sales force.
As the year winds to a close, excitement is rising around the efficacy and availability …
The top ten news stories this week focus on herd immunity, as the Director of …